Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Plenty of serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed so far, thus documenting the importance of evaluating the relevant features of the immune response to this viral agent. The performance of these assays is currently under investigation. Amongst them, LIAISON® SARS-CoV-2 S1/S2 IgG by DiaSorin and Elecsys Anti-SARS-CoV-2 cobas® by Roche are currently used by laboratory medicine hospital departments in Italy and many other countries. In the present study, we firstly compared two serologic tests on serum samples collected at two different time points from 46 laboratory-confirmed coronavirus disease-2019 (COVID-19) subjects. Secondly, 85 negative serum samples collected before the SARS-CoV-2 pandemic were analyzed. Thirdly, possible correlations between antibody levels and the resulting neutralizing activity against a clinical isolate of SARS-CoV-2 were evaluated. Results revealed that both tests are endowed with low sensitivity on the day of hospital admission, which increased to 97.8% and 100% for samples collected after 15 days for DiaSorin and Roche tests, respectively. The specificity evaluated for the two tests ranges from 96.5% to 100%, respectively. Importantly, a poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study. These data further shed light on both potentials and possible limitations related to SARS-CoV-2 serology. In this context, great efforts are still necessary for investigating antibody kinetics to develop novel diagnostic algorithms. Moreover, further investigations on the role of neutralizing antibodies and their correlate of protection will be of paramount importance for the development of effective vaccines.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675753 | PMC |
| http://dx.doi.org/10.1002/jmv.26605 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Can Sex-based Variations in the Immune Responses to AAV Gene Therapy Affect Safety and Efficacy? A Review of Current Understanding.
AAPS J
September 2025
Gene Transfer and Immunogenicity Branch, Division of Gene Therapy 2, Office of Gene Therapy, Office of Therapeutic Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, WO52 RM3124, 10903 New Hampshire Ave, Silver Spring, Maryland, 20993-0002, USA.
As the field of gene therapy advances and as the importance of sex as a biological variable in shaping viral immune responses is recognized, the impact of sex on adeno-associated virus (AAV) vectors mediated gene therapies remain largely unexplored. Here we review current understanding of the immune response against AAV gene therapy as well as the knowledge of sex differences observed in viral responses. We discuss sex differences in innate immune mechanisms such as Toll-like receptor recognition and complement activation, as well as the functional responses of key immune cells such as dendritic cells, macrophages, and T/B cells that are involved in AAV immunogenicity.
View Article and Find Full Text PDFNeonatal Liver-Derived FTH1-Enriched Extracellular Vesicles Attenuate Ferroptosis and Ameliorate MASLD Pathogenesis.
Free Radic Biol Med
September 2025
Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China. Electronic address:
Metabolic dysfunction-associated steatotic liver disease (MASLD), a leading cause of chronic liver pathology, lacks effective therapies. This study identifies ferroptosis-a lipid peroxidation-driven, iron-dependent form of cell death-as a central pathogenic mechanism in MASLD. Integrative proteomic and histopathological analyses of human and murine MASLD livers revealed marked ferroptosis activation, characterized by dysregulated iron metabolism (reduced FTH1 and GPX4; elevated ACSL4) and oxidative stress.
View Article and Find Full Text PDFMorally offensive scientific findings activate cognitive chicanery.
Ann N Y Acad Sci
September 2025
University of Pennsylvania, Philadelphia, Pennsylvania, USA.
We document a mutually reinforcing set of belief-system defenses-cognitive chicanery-that transform "morally wrong" scientific claims into "empirically wrong" claims. Five experiments (four preregistered, N = 7040) show that when participants read identical abstracts that varied only in the sociomoral desirability of the conclusions, morally offended participants were likelier to (1) dismiss the writing as incomprehensible (motivated confusion); (2) deny the empirical status of the research question (motivated postmodernism); (3) endorse claims inspired by Schopenhauer's stratagems (The Art of Being Right) and the Central Intelligence Agency's (CIA's) strategies for citizen-saboteurs; and (4) endorse a set of contradictory complaints, including that sample sizes are too small and that anecdotes are more informative than data, that the researchers are both unintelligent and crafty manipulators, and that the findings are both preposterous and old news. These patterns are consistent with motivated cognition, in which individuals seize on easy strategies for neutralizing disturbing knowledge claims, minimizing the need to update beliefs.
View Article and Find Full Text PDFEvaluation of the C protein of BVDV as a vaccine candidate: Immunoprotective studies in mice.
Vet Microbiol
September 2025
College of Animal Science and Technology/Laboratory of Functional Microbiology and Animal Health, Henan University of Science and Technology, Luoyang 471023, PR China; Luoyang Key Laboratory of Live Carrier Biomaterial and Animal Disease Prevention and Control, Henan University of Science and Techno
Bovine Viral Diarrhea Virus (BVDV) is a major pathogen associated with calf diarrhea and reproductive disorders in cattle. This study evaluated the immune-protective potential of a subunit vaccine based on the capsid C protein of the BVDV HNL-1 strain. In mice model, the C protein subunit vaccine exhibits a favorable safety and elicits robust immune-protective efficacy comparable to commercial inactivated vaccines.
View Article and Find Full Text PDFNon-neutralizing antibodies to influenza A matrix-protein-2-ectodomain are broadly effective therapeutics and resistant to viral escape mutations.
Sci Adv
September 2025
The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Influenza A viruses remain a global health threat, yet no universal antibody therapy exists. Clinical programs have centered on neutralizing mAbs, only to be thwarted by strain specificity and rapid viral escape. We instead engineered three non-neutralizing IgG2a mAbs that target distinct, overlapping epitopes within the conserved N terminus of the M2 ectodomain (M2e).
View Article and Find Full Text PDF